Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
2013 · Blood Cancer Journal · 73 citations
https://doi.org/10.1038/bcj.2013.27
A
Angèle Kelder
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
84
Papers
2.9K
Citations
24
h-index
33
i10-index
Angèle Kelder is an academic researcher from Amsterdam Neuroscience. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Hematopoietic Stem Cell Transplantation & Cancer Genomics and Diagnostics. The author has an h-index of 24, co-authored 72 publications.
ORCID: 0000-0002-9643-4932Papers by this author
worksResidual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib
2011 · Leukemia · 34 citations
https://doi.org/10.1038/leu.2011.347
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
2023 · Cytometry Part B Clinical Cytometry · 16 citations
https://doi.org/10.1002/cyto.b.22144
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization
2018 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.7449368
AML-348 Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)01187-x
Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)00497-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat